For Institute program-specific acronyms, go to NIAID Profile and Fact Book.
For electronic grant applications, a Table of Contents is generated automatically.
For paper applications, go to Form Page 3 in the paper PHS 398 Grant Application.
Form listing potential populations to be enrolled for human subjects research.
For paper grant applications use the Planned Enrollment Report. For electronic applications, use the Planned Enrollment Report form in your Grant Application Package.
Also see SF 424 Application Guide and Inclusion Enrollment Report.
Go to these NIH resources:
Go to these NIAID resources:
Research funded from an NIH institute's set-aside of dollars for a scientific area. Institutes solicit research using requests for applications for grants and solicitations for contracts. See the converse unsolicited research, investigator-initiated, and program announcement.
Conditions determined by a contracting officer during pre-solicitation for evaluating the technical merit of contract proposals responding to a solicitation.
Go to NIAID's Peer Review of R&D Contract Technical Proposals SOP.
Panel of peer reviewers with scientific or technical expertise who conduct initial peer review of the scientific and technical merit of R&D contract proposals. They vote on acceptability and make other recommendations.
Report prepared by a scientific review officer after initial peer review of R&D contract proposals stating scores, strengths, and weaknesses and indicating whether acceptable or unacceptable.
Sharing of knowledge and facilities among federal laboratories, industry, universities, government, and others to make federally generated scientific and technological advances accessible to private industry and state and local governments.
Go to NIH's Office of Technology Transfer and NIAID's Technology Transfer and Intellectual Property Office.
NIAID office that manages NIAID's portfolio of patents and inventions and facilitates collaborations between NIAID intramural researchers and external organizations through CRADAs and other agreements. See technology transfer and Material Transfer Agreement.
Discontinuing a clinical investigation before its completion by a sponsor or by withdrawal of institutional review board or FDA approval.
Go to 21 CFR 812.3, 21 CFR 56.113, and 21 CFR 312.44.
Government contract termination that does not hold a contractor at fault, usually done when in the government's best interest. Nonprofit and educational organizations can be terminated for convenience, but not for default.
Go to these resources:
Government contract termination that holds a contractor at fault for failure to make progress or comply with provisions of a contract. This action is appropriate only in cost-plus-fixed-fee and fixed-price contracts.
Go to FAR 49.
Permanent withdrawal of a grantee's authority to use NIH grant funds due to a failure to comply with the terms and conditions of award.
NIH legal requirements for a grant or contract, based on statute, regulation, or policy. Terms are described in a Notice of Award or contract. See NIAID's Clinical Terms of Award and select agent.
See Clinical Terms of Award.
FDA term for drugs, devices, biologicals, medical devices, human food or color additives, electronic products, or other item regulated by FDA. Go to 21 CFR 56.102 and full 21 CFR 56.
Total allowed costs, both direct and facilities and administrative, incurred by a grantee to carry out a project or activity. These include costs charged to a grant or paid by a grantee to satisfy a matching or cost-sharing requirement.
Stem cell that can differentiate into all types of endoderm, ectoderm, and mesoderm cells. Compare with multipotent, oligopotent, pluripotent, and unipotent stem cells.
National Research Service Award Institutional Research Training Grant (T32) and Short-Term Institutional Research Training Grant (T35). These grants provide domestic, nonprofit, and private or public graduate-level academic institutions with funds for training predoctoral and postdoctoral candidates.
Ability of a cell of one tissue, organ, or system to differentiate into a different cell type.
FDA procedure for giving patients with serious or life-threatening diseases access to investigational new drugs outside a clinical trial. See investigational new drug application.
Go to 21 CFR 312.34 and 21 CFR 312.36.
See streamlined review.
See Technology Transfer and Intellectual Property Office, NIAID.
See application type and activity code.
Last Updated September 30, 2013
Last Reviewed May 08, 2012